The researchers found that exposure to DMTs was not associated with spontaneous abortions, preterm birth, or major congenital anomalies. (HealthDay News) — Disease-modifying therapy (DMT) use for ...

—Data from this real-world study revealed that patients with MS being treated with DMTs had a disproportionally higher number of cases of herpes zoster compared with patients treated with other ...

A significant portion of patients with multiple sclerosis (MS) can achieve a stable disease state when treated with modern disease-modifying therapy (DMT), especially when started early in the disease ...

In multiple sclerosis (MS), a person's immune system attacks the protective covering (myelin sheath) of nerve fibers in the brain and spinal cord (central nervous system). MS disease-modifying ...

Please provide your email address to receive an email when new articles are posted on . Greater comorbidity burden was associated with a higher rate of adverse events. Patients with comorbidities were ...

Multiple Sclerosis (MS), an autoimmune disease which impacts on the brain, spinal cord and optic nerve, is controllable. Those affected by MS, a disorder of the young, can lead a normal life – work, ...

BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...

BUFFALO, N.Y. — In recent years, new drugs to treat multiple sclerosis have significantly improved both the quality of life and longevity for patients with MS. Many of them now live well into their ...

There is currently no cure for Multiple Sclerosis (MS). Patients rarely do well with no therapy at all, and it is generally recommended that patients with a confident diagnosis of MS begin treatment ...

MINNEAPOLIS — Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women’s childbearing years, even when those drugs have been shown to be ...

BUFFALO, N.Y. – In recent years, researchers studying multiple sclerosis have concluded that white matter lesion volume in the brain, long considered the best way to monitor MS disease progression, ...

SAN DIEGO — Tolebrutinib, a novel Bruton’s tyrosine kinase (BTK) inhibitor that targets neuroinflammation, slowed disability progression by 31% in patients with nonrelapsing secondary progressive ...